- IRMS - Nicolae Testemitanu SUMPh
- 2. FACULTATEA DE MEDICINĂ nr.1 / FACULTY OF MEDICINE nr.1
- Departamentul Medicină Internă
- Disciplina de medicină internă – semiologie
- ARTICOLE ȘTIINȚIFICE
Please use this identifier to cite or link to this item:
http://hdl.handle.net/20.500.12710/2023
Title: | Consecinţele timpurii ale miopatiilor inflamatorii idiopatice |
Other Titles: | Early consequences of idiopathic inflammatory myopathies |
Authors: | Loghin-Oprea, Natalia Vetrilă, Snejana Mazur-Nicorici, Lucia Mazur, Minodora |
Issue Date: | 2017 |
Publisher: | Sănătate Publică, Economie şi Management în Medicină |
Abstract: | Idiopathic infl ammatory myopathies (IIM) are a group of
rare diseases characterized by asthenia of skeletal muscles.
Early approach to disease leads to a favorable evolution
of the disease and less outcomes. The aim of this study is
to assess the short-term outcomes in patients with IIM.
We conducted a transversal study enrolling 12 patients
(7 women, 5 men) with IIM, the mean age was 54.1±12.1
(30–67) years and the follow–up period was 16±9.4, (7-25)
months. Patients were assessed by aplying specifi c questionnaires
and modern, validated clinical tools.We found in all
patients muscle damage manifested by muscular dysfunction
– 11 (91.7%) patients and atrophy in one (8,3%) patient, confi rmed by moderate muscle strengh, which implies disability
– 10 (83.3%) patients. Gastrointestinal damage was
manifested by dysphagia in 3 (25.0%) patients, hepatic
steatosis – 3 (25.0%), dismotility – 5 (41.7%) patients. Endocrine
damage like dyslipidemia had 4 (33.3%), secondary
amenorrhea – 4 (33.3%), diabetes mellitus in 2 (16.6%)
patients. Despite moderate disease activity the most common
disease outcomes obtained were muscular – 100% patients,
gastrointestinal – 91.7% and endocrine – 83.3% patients. |
URI: | http://public-health.md/CM3_73_2017cg.pdf http://repository.usmf.md/handle/20.500.12710/2023 |
ISSN: | 1729-8687 |
Appears in Collections: | ARTICOLE ȘTIINȚIFICE
|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
|